News Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
2/11/2019
4:00 PM ET
Press Release

Poster Presented at International Stroke Conference Describing Diffusion’s On-Ambulance Phase 2 Trial with TSC for Treating Acute Stroke

2/11/2019

CHARLOTTESVILLE, Va., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
1/3/2019
9:00 AM ET
Press Release

Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market

1/3/2019

CHARLOTTESVILLE, Va., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
12/17/2018
9:55 AM ET
Press Release

U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic

12/17/2018

CHARLOTTESVILLE, Va., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
12/13/2018
2:00 PM ET
Press Release

Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan

12/13/2018

CHARLOTTESVILLE, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical con...

 Continue Reading
11/15/2018
9:15 AM ET
Press Release

Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology

11/15/2018

Poster Presentation to Focus on Phase 3 GBM Brain Cancer Clinical Trial; 40 Percent Survival Rate for Biopsy-only Patients in Phase 2 Represents Fourfold Increase Above Historical Average For Those Fa...

 Continue Reading
11/14/2018
9:00 AM ET
Press Release

Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

11/14/2018

Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer

CHARLOTTESVILLE, Va., Nov. 14, 2018 (GLOBE NE...

 Continue Reading
10/15/2018
12:00 PM ET
Press Release

Diffusion Pharmaceuticals Chief Financial Officer William “Bill” Hornung to Present at 2018 BIO Investor Forum

10/15/2018

Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment

CHARLOTTESVILLE, Va., Oc...

 Continue Reading
Displaying 1 to 7 (of 108 releases)